Related Experiment Video
Updated: Jun 26, 2026
12:34
The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology
Published on: January 12, 2024
Bullous pemphigoid in an infant using complementary medicine
D J Purvis1, B S Bhogal, J I Harper
1Dermatology Department, Great Ormond Street Hospital for Children, London, UK. djpurvis@slingshot.co.nz
Clinical and Experimental Dermatology
|February 4, 2009
Summary
Bullous pemphigoid (BP), a rare blistering disease, can occur in infants. This case study shows successful treatment of infantile bullous pemphigoid with oral corticosteroids, with complementary medications potentially acting as triggers.
Area of Science:
- Dermatology
- Immunology
- Pediatrics
Background:
- Bullous pemphigoid (BP) is typically an acquired immunobullous disorder affecting the elderly.
- Infantile bullous pemphigoid is exceptionally rare, presenting unique diagnostic and management challenges.
Observation:
- A case of bullous pemphigoid in an infant is presented.
- The infant's condition was associated with the use of complementary medications.
- The clinical presentation involved the characteristic blistering lesions of bullous pemphigoid.
Findings:
- Successful treatment of infantile bullous pemphigoid was achieved using oral corticosteroids.
- Complementary medications were identified as potential triggering factors for the onset of BP in this infant.
Implications:
- This case highlights the possibility of bullous pemphigoid in infants and suggests a potential link to environmental factors or medications.
- Oral corticosteroids represent an effective treatment modality for infantile bullous pemphigoid.
- Further investigation into the role of complementary medications in triggering autoimmune blistering diseases in children is warranted.
